Vitamin B12 metabolism and massive-dose methyl vitamin B12 therapy in Japanese patients with multiple sclerosis.
Serum vitamin B12 levels and unsaturated vitamin B12 binding capacities were measured in 24 patients with multiple sclerosis (MS), 73 patients with other neurological disorders and 21 healthy subjects. There was no decrease in the vitamin B12 levels, however, a significant decrease in the unsaturated vitamin B12 binding capacities was observed in patients with MS when compared with other groups. A massive dose of methyl vitamin B12 (60 mg every day for 6 months) was administered to 6 patients with chronic progressive MS, a disease which usually had a morbid prognosis and widespread demyelination in the central nervous system. Although the motor disability did not improve clinically, the abnormalities in both the visual and brainstem auditory evoked potentials improved more frequently during the therapy than in the pre-treatment period. We therefore consider that a massive dose methyl vitamin B12 therapy may be useful as an adjunct to immunosuppressive treatment for chronic progressive MS.
Kira
J
J
Department of Neurology, Faculty of Medicine, Kyushu University, Fukuoka.
Tobimatsu
S
S
Goto
I
I
D000328:Adult; D000344:Afferent Pathways / Q000187:drug effects / Q000503:physiopathology; D002908:Chronic Disease; D004341:Drug Evaluation; D005071:Evoked Potentials / Q000187:drug effects; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009046:Motor Neurons / Q000502:physiology; D009103:Multiple Sclerosis / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D009135:Muscular Diseases / Q000097:blood / Q000503:physiopathology; D009422:Nervous System Diseases / Q000097:blood / Q000503:physiopathology; D014805:Vitamin B 12 / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000097:blood* / Q000627:therapeutic use
C019476:mecobalamin; D014805:Vitamin B 12